AstraZeneca's anticoagulant reversal agent Andexxa was given an accelerated approval by the FDA in 2018, but the company's plan to get that upgraded to a full approval is facing some pushback.

Journal of Hospital Medicine. 2012;7(3):262-269.

As recommendations may change, clinicians should always consult a regional poison control center (1-800-222-1222) to ascertain the most current recommendations on antidote use and to report ...